UPSTREAM BIO, INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
UPSTREAM BIO, INC. (UPB) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $39.70 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $39.70M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $43.40M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $21.40M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $23.00M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $39.70M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $43.40M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $21.40M 10-K · filed 2026-03-26 |
| 2025-09-30 | $23.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $24.40M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $23.40M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $15.60M 10-K · filed 2025-03-12 |
| 2024-09-30 | $14.10M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |